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HumanAfricantrypanosomiasis(HAT)orsleepingsicknessis
caused by the parasites Trypanosoma brucei (T.b.) gambiense
or T.b. rhodesiense and is fatal if untreated. The ﬁrst stage
following infection corresponds to trypanosome proliferation
in the peripheral system. The disease enters the second stage
when the parasites establish within the CNS. Once within the
CNS, the parasites are considered protected against pentam-
idine and suramin (stage 1 drugs) by the blood–CNS
interfaces (Raseroka and Ormerod 1986; Bronner et al.
1991; Balasegaram et al. 2006; Sanderson et al. 2007). These
consist of the blood–brain barrier (BBB), located at the
cerebral capillary endothelium, and the blood–CSF barrier,
formed by the choroid plexuses and arachnoid membrane.
Hence HAT treatment is stage-speciﬁc and it is assumed that
the stage 2 drugs, melarsoprol and eﬂornithine, must cross the
blood–CNS barriers well (Masocha et al. 2007; Priotto et al.
2008). Melarsoprol is a toxic arsenical derivative which
causes a post-treatment reactive encephalopathy in 5–10% of
patients, resulting in a case-fatality rate of 50% (Kennedy
2004). Furthermore, an increase in melarsoprol treatment
failure has been noted (Brun et al. 2001). Eﬂornithine, an
ornithine decarboxylase inhibitor, is active against second
stage T.b. gambiense, but not T.b. rhodesiense, because of its
high ornithine decarboxylase turnover (Iten et al. 1997).
Studies indicate that eﬂornithine is safer than melarsoprol
against T.b. gambiense HAT (Chappuis et al. 2005; Balase-
garam et al. 2006; Priotto et al. 2008). Nevertheless, eﬂorni-
thinemonotherapyisnotalong-term solution.Thisregimenis
expensive, complicated to administer, less effective in HIV-
endemic areas and could cause parasite resistance. New drug
candidates, especially for stage 2, are urgently required. In
additiontoCNSefﬁcacymodels,emphasishasbeenplacedon
screening compounds for their ability to cross the BBB.
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Abstract
Drugs to treat African trypanosomiasis are toxic, expensive
and subject to parasite resistance. New drugs are urgently
being sought. Although the existing drug, eﬂornithine, is as-
sumed to reach the brain in high concentrations, little is known
about how it crosses the healthy and infected blood–brain
barrier. This information is essential for the design of drug
combinations and new drugs. This study used novel combi-
nations of animal models to address these omissions. Eﬂor-
nithine crossed the healthy blood–CNS interfaces poorly, but
this could be improved by co-administering suramin, but not
nifurtimox, pentamidine or melarsoprol. Work using a murine
model of sleeping sickness demonstrated that Trypanosoma
brucei brucei crossed the blood–CNS interfaces, which re-
mained functional, early in the course of infection. Concen-
trations of brain parasites increased during the infection and
this resulted in detectable blood–brain barrier, but not choroid
plexus, dysfunction at day 28 post-infection with resultant in-
creases in eﬂornithine brain delivery. Barrier integrity was
never restored and the animals died at day 37.9 ± 1.2. This
study indicates why an intensive treatment regimen of eﬂor-
nithine is required (poor blood–brain barrier penetration) and
suggests a possible remedy (combining eﬂornithine with sur-
amin). The blood–brain barrier retains functionality until a late,
possibly terminal stage, of trypanosoma infection.
Keywords: Blood–brain barrier, choroid plexus, eﬂornithine,
trypanosomiasis.
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CNS. In fact, discovery programmes aimed at identifying
drugs for CNS disorders are more likely to fail than
programmes in other therapeutic areas (Reichel 2006). New
molecules against late-stage HAT are unlikely to be available
in the near future. Alternative approaches have been to
optimize the existing drug regimens and to develop combi-
nation chemotherapies to improve efﬁcacy. Trials have been
conducted using eﬂornithine with melarsoprol or nifurtimox,
which is available for compassionate use against HAT.
Although, the eﬂornithine-melarsoprol trial was terminated
because of excessive fatalities, the eﬂornithine–nifurtimox
combination remains promising (Priotto et al. 2007). This
improved efﬁcacy may be due to increased CNS drug entry,
but this has not been investigated. This lack of knowledge
regarding the underlying synergistic mechanisms means that
the full potential of drug combinations is not being exploited
(Burri and Brun 2003).
Despite its importance in understanding anti-trypanosomal
drug delivery, the function of the blood–brain and blood–
CSF barriers throughout the course of trypanosomiasis is
unknown. Early localization of the parasites to the circum-
ventricular organs (CVOs), meninges and CSF has been
reported (Jennings and Gray 1983; Schmidt 1983; Schultz-
berg et al. 1988; Keita et al. 1997). BBB damage occurs in
the late-stage of T.b. brucei rodent infections (Philip et al.
1994) and transient increases in paracellular permeability co-
ordinate with T.b. rhodesiense movement across the human
BBB in vitro (Grab et al. 2004; Nikolskaia et al. 2008). An
understanding of eﬂornithine distribution in the healthy and
infected CNS is essential if we are to improve efﬁcacy,
reduce toxicity and design new drug combinations. Investi-
gating the effects of infection on barrier integrity should also
clarify the importance of CNS delivery for HAT drugs.
In this study, we used well-established methods in com-
bination: the sensitive in situ brain/choroid plexus perfusion
method and a murine model of late-stage HAT (Jennings
et al. 2002; Sanderson et al. 2007). Studies explored the
pharmacokinetic characteristics of eﬂornithine transport
across the healthy blood–CNS interfaces both alone and with
other anti-trypanosomal agents. The potential removal of
eﬂornithine by the BBB efﬂux transporter, P-glycoprotein
(P-gp), was also investigated using P-gp-deﬁcient and wild-
type mice. Further studies explored eﬂornithine drug delivery
and blood–CNS barrier integrity at set time-points in mice
that had been infected with T.b. brucei GVR 35 and attempted




3H]Eﬂornithine hydrochloride was custom radiolabelled (500 mCi/
mmol, radiochemical purity 97.6%; Moravek, CA, USA). [
14C]Su-
crose (498 mCi/mmol, radiochemical purity ‡ 98%) and
D-[1-
3H(N)]-mannitol (14.2 Ci/mmol, radiochemical purity > 97%)
were purchased [Moravek and Perkin-Elmer (Boston, MA, USA),
respectively]. Eﬂornithine hydrochloride, suramin, and pentamidine
isethionate sodium salt were purchased from Sigma (Dorset, UK).
Nifurtimox and melarsoprol were a gift (Professor Croft; London
School of Hygiene and Tropical Medicine, UK).
Animals
Procedures were performed within the animal scientiﬁc procedures
act (1986) and speciﬁed animal pathogen order (1998) guidelines.
BALB/c mice were purchased (Harlan; Oxon, UK). A breeding
colony of FVB-Mdr1a/1b(+/+) and FVB-Mdr1a/1b()/)) mice
(Taconic; NY, USA) was established and genotype conﬁrmed by
PCR analysis (Harlan). Dr. Alfred Schinkel (Netherlands Cancer
Institute) is the creator of Mdr1a/1b mice. Mice were maintained
under standard temperature/lighting conditions and given food and
water ad libitum.
Characterization of T.b. brucei GVR 35 infection in BALB/c mice
A murine model of HAT which uses cloned stabilates of T.b.
brucei GVR 35 to infect outbred CD1 mice is established and
exhibits many of the human neuropathological changes (Jennings
et al. 2002). In the present study, T.b. brucei GVR35/C1.7 was
passaged through inbred BALB/c mice. Parasitaemia was esti-
mated using the ‘Matching Method’ (Herbert and Lumsden 1976).
At peak parasitaemia, blood was obtained by cardiac puncture,
preserved under liquid nitrogen and was used to infect all the
mice. Mice were infected by i.p. injection of 2 · 10
4 trypanosomes
diluted in 0.1 mL phosphate-buffered saline containing 15 g/L
glucose pH8.0 (PBS-G) and the mean survival time calculated.
Parasitaemia was monitored, using an improved Neubauer haem-
ocytometer, in venous blood collected using heparin-ﬂushed
(1000 U/mL) red blood cell pipettes and diluted 1 : 100 with
PBS-G. In CD1 mice, the CNS-stage of the disease is reached
between 14 and 21 days post-infection (p.i.) (Jennings and Gray
1983). To determine when the parasites establish within the CNS
in the BALB/c strain, groups of 3–7 mice were infected and
parasitaemia monitored. The mice were treated with diminazene
aceturate [Berenil  Hoechst (Frankfurt, Germany), 40 mg/kg i.p.],
on day 7, 11, 12, 13, 14 or 21 p.i. (Jennings and Gray 1983).
Seven days after Berenil treatment, blood from each mouse was
examined to conﬁrm the absence of systemic trypanosomes. Mice
were anaesthetized (i.p. medetomidine hydrochloride (2 mg/kg)
and ketamine (150 mg/kg)) and perfused via the heart with sterile
saline. Each mouse brain was excised, homogenized in 1 mL
sterile saline and injected i.p. into a naı ¨ve recipient mouse. Whole
blood from the tail vein of recipient mice was checked daily for
parasitaemia up to 28 days p.i. (Jennings et al. 1979, 2002). Since
Berenil is a ﬁrst stage trypanocidal drug, this treatment will not
cure infections that have progressed to the CNS. Therefore, any
trypanosomes detected in the recipient mice have been transferred
in the brain homogenate indicating the presence of CNS disease in
the original animals (Jennings et al. 1979).
In situ perfusion technique
The heart perfusion method was used as described by Sanderson
et al. (2007). Adult male mice (25 g) were anaesthetized as above
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60 min. After perfusion, a cisterna magna CSF sample was taken,
the animal decapitated and brain removed. Samples of frontal
cortex, occipital cortex, caudate putamen, hippocampus, hypothal-
amus, thalamus, pons, cerebellum, fourth ventricle choroid plexus,
pineal and pituitary glands were taken. These regions were selected
as they are affected by trypanosomes (Sanderson et al. 2007). All
the brain matter remaining after these samples had been taken,
underwent capillary depletion analysis (Sanderson et al. 2007). In
brief, a brain homogenate was prepared using a buffer and a dextran
solution. Final dextran concentration was 13%. Centrifugation of
this homogenate produced an endothelial cell-enriched pellet and a
brain parenchyma containing supernatant. Capillary depletion
(including brain homogenate, supernatant and pellet), brain regions,
CVOs, CSF and plasma samples were solubilized by 3.5 mLs
Solvable (Perkin-Elmer; 0.5 mLs). Lumasafe scintillation ﬂuid
(Perkin-Elmer) was then added. Sample radioactivity was quantiﬁed
(Packard Tri-Carb 2900TR counter).
Experimental design
Multiple-time experiments
Heart perfusions were performed in BALB/c mice. [
3H]eﬂornithine
(1 lM) and [
14C]sucrose (1 lM) were present in the artiﬁcial
plasma for up to 30 min. [
14C]sucrose is a baseline marker. In brain
samples, it measured vascular space. Any deviation from the norm
indicated loss of BBB integrity or under-perfusion of the tissue. In
pineal and pituitary gland samples, [
14C]sucrose measures vascular
space and reﬂects the ability of [
14C]sucrose to cross between
endothelial cells. Thus, also provides a measure of the paracellular
permeability characteristics of these tissues. In choroid plexus,
[
14C]sucrose, additionally represents the extracellular space formed
between the choroidal capillary endothelium and epithelium.
Effect of drug on barrier integrity
The effect of prolonged eﬂornithine (250 lM) exposure on barrier
integrity was observed by perfusing BALB/c mice for 60 min. In the
ﬁnal 10 min [
3H]mannitol (0.035 lM) and [
14C]sucrose (1 lM)
were also included in the artiﬁcial plasma. [
3H]mannitol also
measures vascular and extracellular space. However, its small size
(MW182) allows it to be more sensitive than [
14C]sucrose (MW342)
to alterations in barrier integrity. Results were compared with mice
that were perfused in the absence of eﬂornithine.
Transporter investigations
To investigate the role of P-gp on eﬂornithine transport, FVB-
Mdr1a/Mdr1b(+/+) and FVB-Mdr1a/Mdr1b()/)) mice were per-
fused (30 min) with [
3H]eﬂornithine (1 lM) and [
14C]sucrose
(1 lM). To determine whether eﬂornithine distribution was
affected by a saturable system, 10 min perfusions were performed
using BALB/c mice and artiﬁcial plasma containing [
3H]eﬂorni-
thine (1 lM) and [
14C]sucrose (1 lM) and unlabelled
anti-trypanosomal drug at concentrations comparable to those
measured in the plasma of treated patients [either 250 lM
eﬂornithine, 150 lM suramin, 200 lM suramin (Milord et al.
1993), 10 lM pentamidine (Waalkes and DeVita 1970), 30 lM
melarsoprol or 6 lM nifurtimox (Gonzalez-Martin et al. 1992)].
Each experiment also involved a pre-isotope perfusion period of
10 min. During this pre-isotope perfusion, the plasma also
contained the unlabelled drugs. Control experiments mirrored
these experiments except no unlabelled drugs were present
throughout the perfusion.
Effect of parasite on barrier integrity/permeability
To investigate the effects of infection on barrier integrity and drug
penetration BALB/c mice were infected with T.b. brucei as
described. At day 7, 14, 21, 28 and 35 p.i., groups were in situ
perfused with [
3H]eﬂornithine (1 lM) and [
14C]sucrose (1 lM) for
30 min. The fourth ventricle choroid plexus weight was monitored.
Expression of results
Tissue radioactivity (dpm/g) was expressed as a percentage of that
in plasma (dpm/mL) and termed RTissue (mL/100 g). Where stated,
the RTissue for eﬂornithine has been corrected for vascular/
extracellular space by subtraction of the [
14C]sucrose RTissue
value. Blood-to-brain unidirectional rate constants (Kin) were
determined by single-time uptake analysis (Kin =[
14C]sucrose
corrected RTissue values/perfusion time) after 30 min perfusions
(Williams et al. 1996).
HPLC analysis
To ensure the integrity of [
3H]eﬂornithine during passage through the
cerebral circulation, samples of arterial inﬂow and venous outﬂow,
collected at 10, 20 and 30 min, were analysed by HPLC (Jasco,
Essex,UK).Samples(100 lL)werepassedthroughaHamiltonPRP-
X300, 7 lm (250 · 4.1 mm) column using 0.3 mL/min 30 mM
potassium dihydrogen phosphate buffer (adjusted to pH2.2 with 85%
orthophosphoric acid) and acetonitrile (50 : 50) over 35 min (Han-
pitakpong et al. 2003). The column eluant was then mixed 1 : 3 with
scintillation ﬂuid (UltimaFlo M; Perkin-Elmer) in a radioactive
detector (Packard, UK) to allow real-time radioactive analysis.
Octanol-saline partition coefﬁcient and protein binding
An octanol-saline partition coefﬁcient (pH 7.4) was determined for
[
3H]eﬂornithine (0.67 lM). Binding of [
3H]eﬂornithine (0.4 lM) to
murine (male FVB) and human (Sigma) plasma proteins and to the
artiﬁcial plasma bovine serum albumin and dextran, was measured
using Centrifree micropartition devices (MA, USA) (Sanderson
et al. 2007). Lyophilized human plasma was reconstituted in 1 mL
deionized water.
Data Analysis
Comparisons were made between appropriate groups and differ-
ences at the 5% level considered signiﬁcant. Two-way ANOVA
followed by Tukey’s multiple range test was employed in each
case using Sigma Stat software (SPSS Software Ltd, Birmingham,




No differences in [
14C]sucrose/vascular space values (RTissue)
were observed between the frontal cortex, caudate putamen,
occipital cortex, hippocampus, hypothalamus and thalamus
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(30 min). This was smaller than that measured in pons and
cerebellum (3 mL/100 g; p < 0.001). These results are
comparable to published values (Sanderson et al. 2007).
[
3H]eﬂornithine RTissue values were higher than those for
[
14C]sucrose (Fig. 1; p < 0.01 for all brain regions except the
caudate putamen, where the difference did not attain
statistical signiﬁcance). When corrected for vascular space,
the RTissue values for [
3H]eﬂornithine reached only 1–4 mL/
100 g in the brain at 30 min (equivalent to 10–40 nM or
0.003–0.011% of administered dose). The [
14C]sucrose-
corrected distribution of [
3H]eﬂornithine over time was
higher in the hypothalamus (Kin; 1.3 ± 0.4 lL/min/g) when
compared with the caudate putamen (0.5 ± 0.2 lL/min/g)
and hippocampus (0.5 ± 0.2 lL/min/g) (p = 0.021 and
p = 0.043, respectively), but not to other regions includ-
ing frontal cortex (0.6 ± 0.2 lL/min/g), occipital cortex
(0.6 ± 0.2 lL/min/g), pons (1.2 ± 0.4 lL/min/g), cerebellum
(1.0 ± 0.3 lL/min/g) and thalamus (0.9 ± 0.2 lL/min/g).
[
3H]eﬂornithine was detected in brain homogenate, super-
natant and capillary endothelial cell-enriched pellet at higher
RTissue levels than [
14C]sucrose (Fig. 1; p = 0.001, p = 0.011
and p = 0.02 respectively). When corrected for [
14C]sucrose
space, the distribution of [
3H]eﬂornithine was only 2.0 ± 0.8,
1.6 ± 0.5 and 0.4 ± 0.2 mL/100 g respectively after 30 min
(equivalent to 20, 16 and 4 nM or 0.005, 0.004 and 0.001%
of administered dose, respectively).
[
3H]eﬂornithine RTissue in the pineal and pituitary glands
was higher than that achieved for [
14C]sucrose (p = 0.002
and 0.023 respectively). When corrected for vascular space,
[
3H]eﬂornithine distribution reached 48 ± 16 and 26 ±
11 mL/100 g in the pineal and pituitary glands respectively
(30 min). Overall, [
3H]eﬂornithine levels measured over time
in the choroid plexus were not different to those achieved for
Fig. 1 RTissue values for [
3H]eﬂornithine
(—d—) and [
14C]sucrose (–s–) in selected
brain regions, capillary depletion, choroid
plexus and CSF samples plotted against
perfusion time. Supernatant and pellet were
obtained from capillary depletion analysis of
brain homogenate. Values are mean ±
SEM (n = 3–6), except for CSF where
individual points are plotted because of the
limited number of samples.
  2008 The Authors
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14C]sucrose, even though at 30 min [
3H]eﬂornithine reached
16 ± 6 mL/100 g ([




CSF was measured after a 10 min perfusion at 7.9 ± 2.3 and
5.3 ± 1.4 mL/100 g, respectively (RTissue, n = 4). There was
no difference between the CSF concentration of [
3H]eﬂor-
nithine compared to [
14C]sucrose over time (Fig. 1). No
differences were observed between the HPLC chromato-
grams obtained from the arterial and venous samples
collected – data not shown.
Effect of eﬂornithine on barrier
No differences were observed for the vascular markers,
[
14C]sucrose and [
3H]mannitol, in any brain, capillary
depletion or CVO samples when 250 lM unlabelled eﬂor-
nithine was present and compared with controls (p > 0.05 for
each marker and sample type)-data not shown.
Transporter investigations
No differences were observed in the RTissue values achieved
for [
3H]eﬂornithine or [
14C]sucrose for the brain, capillary
depletion samples and CVOs from FVB-mdr1a/1b()/))
compared with FVB-mdr1a/1b(+/+) mice-data not shown.
Since [
3H]eﬂornithine could cross the BBB and be detected
in the brain, experiments were performed with unlabelled
eﬂornithine to investigate whether [
3H]eﬂornithine was
subjected to uptake or efﬂux by a saturable mechanism.
Control studies revealed that the pre-isotope perfusion had no
effect on the percentage of either [
14C]sucrose or [
3H]eﬂor-
nithine detected in brain regions. In addition, no differences
were observed in the vascular space or the RTissue values of
[
3H]eﬂornithine detected in the absence or presence of
250 lM unlabelled eﬂornithine in the artiﬁcial plasma –
(n = 3–7 for each group; data not shown).
Effect of drug combinations on [
3H]eﬂornithine
distribution
Both 150 and 200 lM suramin had no effect on the
[
14C]sucrose RTissue values in any sample. The sucrose-
corrected distribution of [
3H]eﬂornithine into the brain and
CVOs was increased with both suramin concentrations when
compared with controls (Table 1: p < 0.001 for each
concentration). There was a difference in the sucrose-
corrected [
3H]eﬂornithine distribution into the brain
(p < 0.001), but not the CVOs, between the 150 and
200 lM suramin groups. An increase in [
3H]eﬂornithine
distribution ([
14C]sucrose corrected) into all capillary deple-
tion samples in the presence of suramin was also observed
(p = 0.006 for each concentration). This increase was most
evident in the endothelial cell-enriched pellet (Table 1). No
difference was observed between the two concentrations for
the capillary depletion samples.
No differences were observed in the concentrations of
either [
14C]sucrose or [
3H]eﬂornithine in any brain regions,
capillary depletion samples or CVOs sampled when either
unlabelled pentamidine, nifurtimox or melarsoprol were
added to the artiﬁcial plasma (p > 0.05 for each isotope
and drug) – data not shown.
Entry of parasites into the brain
Parasites were detected in the blood from day 3 and this was
quantiﬁable using an improved Neubauer haemocytometer
from day 4–5 (Fig. 2). Mice were observed daily for any
overt signs of infection. At day 7 p.i. the mice displayed no
symptoms apart from a mild piloerection which continued
throughout the infection. By day 21 p.i. the mice had a
swollen abdomen indicating an enlarged spleen. By day 28
p.i. the mice had a more severe piloerection, exhibited longer
Fig. 2 Whole blood parasitaemia in BALB/c mice after infection with
stabilate GVR 35. Mean ± SEM (n = 6–85). Sample size varied be-
cause of amalgamation of all laboratory results to achieve the most
accurate picture of the ﬂuctuations. Average survival time was
37.9 ± 1.18 days.
Table 1 Percentage increase in [
3H]eﬂornithine distribution ([
14C]su-
crose-corrected) observed in the presence of suramin
Region







Frontal cortex 36.4 ± 9.9 46.9 ± 11.0
Hypothalamus 51.2 ± 15.2 170.6 ± 26.0
Pons 59.5 ± 13.6 74.4 ± 17.2
Homogenate 42.2 ± 9.1 58.0 ± 15.2
Supernatant 14.2 ± 13.6 11.8 ± 11.9
Pellet 838.9 ± 386.8 842.6 ± 242.1
Choroid plexus 639.5 ± 85.9 1085.2 ± 497.3
Values obtained in the presence of suramin were all signiﬁcantly
higher compared to control. Each group n = 4–8.
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The average survival time of BALB/c mice following T.b.
brucei infection was 37.9 ± 1.2 days (n = 21). No parasites
were detected in the CNS at day 7 p.i. One out of three
recipient mice that were injected with brain taken from
donors that had been infected for 11 days relapsed. This was
the earliest time that viable parasites were detected in the
CNS. By 13 days p.i. all donor mice had cerebral parasites
and were able to establish patent infections in naı ¨ve
recipients. Recipient mice relapsed earlier when day 21 p.i.
donor mice were used compared with day 14 p.i.: blood
parasites being detected at day 4 and days 7–14 respectively,
in the recipient mice (p = 0.008; Student’s unpaired t-test).
Effect of parasite on barrier integrity/permeability
When compared with uninfected mice, no differences were
observed in the RTissue values for either [
3H]eﬂornithine or
[
14C]sucrose measured in the brain regions of mice that were
infected for 7 to 21 days with T.b. brucei. However, at day
28 p.i., the RTissue values for [
3H]eﬂornithine in all brain
regions were higher than those measured at day 7 p.i.
(p = 0.007), day 14 p.i. (p = 0.025), day 21 p.i. (p < 0.001)
and in uninfected mice (Fig. 3; p < 0.001). A further
increase was also observed in the RTissue values achieved
for [
3H]eﬂornithine in the brain regions at day 35 p.i.
compared with control mice (p < 0.001) as well as day 7 to
day 28 p.i. (p < 0.001 for each time p.i.). Despite an apparent
increase in the vascular/[
14C]sucrose space measured in the
pons at day 28 p.i., overall there was no statistical difference
in [
14C]sucrose accumulation in any brain region at this time-
point compared with non-infected controls. In contrast, a
signiﬁcant increase was observed in all regions at day 35 p.i.
when compared with uninfected mice (p < 0.001).
There was an increase in the RTissue levels of both
[
3H]eﬂornithine and [
14C]sucrose in the capillary depletion
samples at day 35 p.i., but not day 28 p.i., when compared to
the control groups (p < 0.001 for both isotopes). This was
most obvious in the pellet where respective RTissue levels
were increased by 6 and 10 times those measured in
uninfected mice (Fig. 3). In contrast, no signiﬁcant differ-
ences were observed in the [
14C]sucrose RTissue values in the
CVOs at any time-point throughout the course of infection
when compared to uninfected mice (Fig. 4). A small
decrease was observed in the [
3H]eﬂornithine detected in
the CVOs at day 21 p.i. compared with uninfected controls
(p = 0.029 across all CVOs). However, it is important to note
that day 21 p.i. mice were not signiﬁcantly different to other
post-infection time-points. The choroid plexus weight of the
non-infected group (0.322 ± 0.029 mg) was not signiﬁcantly
different from that measured in day 7 (0.270 ± 0.042 mg),
14 (0.337 ± 0.037 mg), 21 (0.289 ± 0.065 mg), 28 (0.362 ±
0.058 mg) or 35 (0.432 ± 0.129 mg) p.i. groups.
Octanol-saline partition coefﬁcients and protein binding
The octanol-saline partition coefﬁcient of [
3H]eﬂornithine
was 0.00487 ± 0.00010. No [
3H]eﬂornithine was detected
Fig. 3 The effect of T.b. brucei infection on
the RTissue values for (a) [
3H]eﬂornithine and
(b) [
14C]sucrose in the brain regions and
capillary depletion samples. Supernatant
and pellet samples were obtained after
capillary depletion analysis of brain
homogenate. BALB/c mice were infected
and perfused on days 7 through 35 p.i. Any
statistical signiﬁcance between the infected
groups when compared with the non-
infected group is noted. *p < 0.001. Each
group n = 5–11.
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plasma or to protein in the mouse or human plasma.
Discussion
Developed as an anti-cancer chemotherapeutic called diﬂu-
oro-methyl-ornithine, eﬂornthine was subsequently shown to
have anti-protozoal activity (Bacchi et al. 1980; McCann
et al. 1981; Van Nieuwenhove et al. 1985) and is now used
in the treatment of stage 2 infection with T.b. gambiense. The
fact that it is effectively used against the CNS-stage has led
to the assumption that it readily crosses the BBB. However,
our study, which directly investigates movement across the
blood–CNS interfaces in situ, but in the absence of systemic
metabolic inﬂuences, shows that eﬂornithine does not cross
the healthy murine BBB well. This is further highlighted by
comparing brain parenchyma (supernatant) unidirectional
transfer constants (Kin; determined by single-time analysis).
Eﬂornithine (0.52 ± 0.18 lL/min/g) and pentamidine (stage
1 drug; 0.68 ± 0.12 lL/min/g) having similar values and
nifurtimox (stage 2 drug 56.7 ± 10.6 lL/min/g) being
greater (unpublished observations). Furthermore, prolonged
exposure of eﬂornithine to the blood–CNS interfaces does
not affect barrier integrity as measured by [
14C]sucrose. This
limited brain distribution of [
3H]eﬂornithine has been
observed after intravenous administration in healthy rats;
permeability coefﬁcients being similar for eﬂornithine
(3.9 · 10
)7 cm/s) (Levin et al. 1983) and the non-permea-
ting molecule, sucrose (1.2 · 10
)7 cm/s) (Levin et al. 1976).
This is unsurprising, if one considers its hydrophilicity
(octanol-saline partition coefﬁcient of 0.00487 ± 0.00010).
In fact, the ability of eﬂornithine to cross the BBB can be
predicted from its physicochemical characteristics (Levin
et al. 1983). Furthermore, eﬂornithine has a short half-life
(3.3 h) and 80% is eliminated via the kidneys in healthy
humans (Burri and Brun 2003). All these factors reduce the
concentration of eﬂornithine that could be achieved in the
brain. In agreement with this current study, eﬂornithine does
not bind signiﬁcantly to plasma proteins (Burri and Brun
2003) or undergo signiﬁcant metabolism in mice (Romijn
et al. 1987). Our study also demonstrates that eﬂornithine
can cross the blood–CSF barrier, although the choroid plexus
levels are low (16 ± 6 mL/100 g) in comparison with
suramin (163 ± 32 mL/100 g) (Sanderson et al. 2007). Eﬂ-
ornithine can diffuse into the CSF of healthy volunteers
(Burri and Brun 2003) and patients with T.b. gambiense
infections (Doua et al. 1987; Taelman et al. 1987;
Na-Bangchang et al. 2004), albeit at low levels (Na-Bang-
chang et al. 2004) and eﬂornithine treatment can clear
parasites from CSF (Milord et al. 1992). Furthermore,
intraventricularly infused eﬂornithine only leaves the ventri-
cles by bulk absorption from the CSF (Levin et al. 1984),
indicating that eﬂornithine movement from the CSF to brain
is limited. This is also apparent in our study as higher levels
of eﬂornithine were detected in the CSF compared with the
brain samples.
Based on the experiments described in this present study
we can estimate that, after a 30 min perfusion, eﬂornithine
reaches a concentration of at least 7 nM in the murine brain.
The IC50 value against bloodstream forms of T.b. gambiense
is considerably higher being 10.7 lg/mL (59.0 lM) for
eﬂornithine (Likeufack et al. 2006). However, it is important
to note that eﬂornithine is a cytostatic rather than a
trypanolytic drug and requires an intact immune system to
elicit a cure. This is obviously lacking in the in vitro system
used to determine IC50. Thus the IC50 value is likely to be an
overestimate and it is impossible to say if therapeutic brain
concentrations of [
3H]eﬂornithine are achieved. However, as
eﬂornithine has to be administered intravenously every 6 h
for 14 days (100 mg/kg body weight) for it to be effective, it
is reasonable to consider that this intensive regimen is, at
least partly, a consequence of limited blood–brain and blood–
CSF barrier penetration. Eﬂornithine induces the differenti-
ation of trypanosomes from the long slender blood-stream
forms to short stumpy non-dividing forms (Gifﬁn et al.
1986). This inhibition of proliferation prevents further
changes in the parasite antigenic repertoire thus making the
Fig. 4 The effect of T.b. brucei infection on the RTissue values of (a)
[
3H]eﬂornithine and (b) [
14C]sucrose in the CVOs. BALB/c mice were
infected and perfused on days 7 through 35 p.i. No statistical differ-
ence was detected between infected and non-infected groups. Each
group n = 5–11.
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tiveness of an intensive eﬂornithine regimen at treating stage
2 HAT may be related to the fact that different forms of the
parasite cannot cross the BBB (Grab et al. 2004), than
ensuring effective brain concentrations of eﬂornithine are
reached. However, eﬂornithine is only administered once the
parasites are detected in the CNS suggesting that the drug has
to reach the CNS to cure the established CNS infection.
Furthermore, one of the major determinants of successful
eﬂornithine treatment seems to be the CSF drug level reached
during treatment, and it was shown that levels above 50 lM
must be reached to attain a consistent clearance of parasites
(Burri and Brun 2003). This indicates that eﬂornithine
movement across the BBB is an important prerequisite for
successful treatment of HAT.
It has been suggested that eﬂornithine is actively or
passively efﬂuxed from the CNS (Na-Bangchang et al.
2004). Eﬂornithine is a cationic amino acid analogue and
facilitated and active transport of cationic amino acids has
been described at the BBB (O’Kane et al. 2006). However,
the physicochemical characteristics of eﬂornithine, together
with our multiple-time and self-inhibition studies, suggest
that a transporter is not involved in the movement of this
molecule into or out of the murine brain. Eﬂornithine enters
murine ﬁbroblasts and bloodstream trypanosomes by passive
diffusion (Bitonti et al. 1986; Delespaux and de Koning
2007). P-glycoprotein is an efﬂux transporter expressed at
the BBB, and hypothesized to contribute to the synergistic
effect of drugs when they are used in combination. Our
studies using mice that do not express P-gp, failed to
produce any changes in the distribution of [
3H]eﬂornithine.
Eﬂornithine appears to cross the blood–CNS interfaces by
diffusion.
In order to simplify treatment, shorten its duration and to
avoid the development of parasite resistance against eﬂorni-
thine, application in combination with the other anti-trypan-
osomal drugs is being considered(Priotto et al. 2007).
A combination of eﬂornithine and suramin proved effective
in curing CNS animal models of T.b. rhodesiense (Bacchi
et al. 1994) and T.b. brucei infections (Clarkson et al. 1984;
Bacchi et al. 1987), although the drugs when used alone
were ineffective (Bacchi et al. 1994). The mechanism
resulting in this potentiation is unknown. It is therefore of
interest that unlabelled suramin increased the measured
[
3H]eﬂornithine in all brain regions in particular the cerebral
capillary endothelial cells in this study. Clearly this could
explain the synergistic effect of eﬂornithine and suramin
combinations. As previously stated the presence of unla-
belled eﬂornithine had no effect on [
3H]eﬂornithine distri-
bution. Furthermore, our earlier study conﬁrmed that
eﬂornithine or suramin had no effect on [
3H]suramin CNS
distribution (Sanderson et al. 2007). However, evidence of
suramin interacting with plasma membranes was found
(Sanderson et al. 2007). Taken together these results indicate
that the interaction of [
3H]eﬂornithine with suramin may be
due to endocytosis of suramin and consequently eﬂornithine.
There was no change in the CNS distribution of [
3H]eﬂor-
nithine when in combination with pentamidine, melarsoprol
or nifurtimox.
This study also examined the integrity of the blood–CNS
interfaces during the course of trypanosome infection using a
murine model of trypanosomiasis. BALB/c mice infected
with the stabilate T.b. brucei GVR 35 survived for 38 days.
CD1 mice infected with this stabilate survive for at least
30 days (Jennings and Gray 1983; Jennings et al. 2002).
BALB/c mice infected with the AnTAT 1/1 clone died 28–
36 days (Schultzberg et al. 1988) and 30 ± 3 days p.i.
(Namangala et al. 2000). Blood parasitaemia ﬂuctuated and
exhibited a similar proﬁle to BALB/c mice infected with
AnTAT 1/1 (Namangala et al. 2000). In this present study
viable parasites were not detected in the brain at day 7 p.i.,
but by day 14 all mice had cerebral parasites. Thus, although
T.b. rhodesiense parasites injected directly into the murine
brain do not survive (Schmidt and Bafort 1987), T.b. brucei
parasites that cross the BBB in vivo remain viable. Parasites
reached the CNS from day 11. Interestingly, the integrity of
the blood–CNS interfaces, as measured by [
14C]sucrose, was
not affected by the presence of cerebral parasites at day 14 or
21 p.i.. Furthermore, greater parasite numbers were present in
the brain at day 21 compared with day 14 p.i.. Increasing
numbers of cerebral parasites has been observed in mice
infected with the AnTAT 1/1 clone (Amin et al. 2008). In
agreement, by day 21 p.i. with T.b. brucei GVR 35 there are
considerable trypanosome numbers within the CNS of CD1
mice (Jennings and Gray 1983). This indicates that either
parasites multiply within the CNS, ﬂuctuating waves of
parasites enter the CNS (possibly linked to the variable blood
parasitemia) and/or parasites continually cross the blood–
CNS interfaces during the course of infection. We found no
evidence for an increase in BBB permeability at the early
time-points, which implies that the parasites do not irrevers-
ibly damage the tight junctional components or endothelial
cells themselves. Interestingly the tight junction proteins,
occludin and zonula occludens 1, are unaffected by T.b.
brucei infections in rats (Mulenga et al. 2001). Furthermore,
T.b. rhodesiense but not T.b. brucei, caused a transient
change in BBB permeability as measured by transendothelial
electrical resistance in a human brain microvessel endothelial
cell line during an overnight parasite incubation (Grab et al.
2004; Nikolskaia et al. 2008). This implies a reversible
change in paracellular permeability and tight junction
integrity with human trypanosome invasion of the CNS.
Murine infection with T.b. brucei GVR 35 results in no
neuropathological ﬁndings at day 7 p.i., a mild meningitis at
day 21 p.i. and a moderate meningitis at day 28 p.i. (Jennings
and Gray 1983). In this study, trypanosome infection only
started affecting the functional integrity of the BBB, as
measured by [
14C]sucrose, late in the infection course (day
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that pass the BBB are required for the treatment of second
stage HAT (Van Nieuwenhove 1999). Interestingly, the
smaller molecule, eﬂornithine (MW237), was able to cross
more rapidly than sucrose (MW342) at day 28. By day 35 p.i.
there was an even greater loss of BBB integrity with
signiﬁcant increases in both [
14C]sucrose and [
3H]eﬂorni-
thine RTissue in all brain regions. This conﬁrms a report of
substantial BBB breakdown in the late phase of T.b. brucei
infection in rats (Philip et al. 1994) and also suggests a
gradual loss of BBB integrity with time rather than a
complete breakdown. Importantly, although the pons
appeared more fragile to this breakdown, statistically no
region was more sensitive to this loss of integrity at either
day 28 or 35 p.i.. Thus we were unable to demonstrate a
direct link to the classical HAT complication of white matter
encephalitis (Kennedy 2004). The [
3H]eﬂornithine and
[
14C]sucrose concentrations in the capillary endothelial
cell-enriched pellet in the day 35 p.i. mice was increased
compared to the non-infected and other infected time groups.
This cannot be explained by an increase in the paracellular
transport of the molecules due to a loss of tight junctional
integrity. However, it may reﬂect an increase in vesicular
trafﬁcking within the endothelial cells.
Therewasnoevidenceofblood–CSFbarrierdysfunctionin
terms of extracellular space changes (e.g. oedema) in the
fourth ventricle choroid plexuses throughout the infection.
Valuesbeing13–20%inbothuninfectedandinfectedanimals,
which is similar to that measured in healthy rats (Smith et al.
1981). Oedema does occur in rabbit choroid plexus during
trypanosome infection (Ormerod and Segal 1973). However,
choroidplexusabnormalities werefocalandwereinconsistent
between lateral and fourth ventricle in rodent T.b. gambiense
and brucei infections (Van Marck et al. 1981; Quan et al.
1999). Furthermore, blood–CSF barrier impairment is not a
permanent feature of T.b. rhodesiense infections in vervet
monkeys (Waitumbi et al. 1988). Importantly, choroid plexus
oedema has been linked to blood–CSF permeability disrup-
tioninanimalmodelsofischemia(EnnisandKeep2006).The
increased ﬂuid volume distending the choroidal epithelium
making the structure more permeable (Murphy and Johanson
1985). Although it is unknown if trypanosomes induce
ischemia, it is noted that whilst the choroid plexus epithelium
is extremely sensitive to ischemia and undergoes signiﬁcant
morphological and functional damage, it does recover quickly
(Johanson et al. 2000). This recovery may reﬂect the
rearrangement of the surviving cells to create a smaller, but
functionalplexusornewepithelialcellsbeingproduced(Keep
and Ennis 2005). However, the choroid plexus weight
remained unchanged during the trypanosome infection sug-
gesting that a damage-recovery process had not occurred or
was undetectable at the time-points measured.
CSF samples are difﬁcult to take in small animals and can
be contaminated by blood or artiﬁcial plasma. Hence only
crystal-clear samples from the healthy animals were taken for
radioactive analysis. [
14C]sucrose CSF levels were also used
to highlight non-visible contamination and samples to be
discarded. In the infected animal model, contamination and
high [
14C]sucrose levels may indicate blood–CSF barrier
breakdown. Although it was noticeable that the CSF samples
became more difﬁcult to obtain as the infection progressed,
the CSF results from the infected animals are impossible to
interpret accurately and we cannot draw any conclusion in
terms of changes to CSF drug penetration during the
infection. In a clinical study the highest drug levels were
obtained with the most severe disease form, suggesting a
penetration into the CSF proportional to the degree of CNS
involvement (Taelman et al. 1987). This may reﬂect BBB
rather than blood–CSF barrier breakdown. In fact, CSF/
serum ratios of eﬂornithine are higher in patients with
melarsoprol-refractory infections, possibly because of severe
BBB impairment leading to increased permeability as a
consequence of chronic meningoencephalitis (Burri and Brun
2003).
To summarize this study highlights the misconception that
eﬂornithine crosses the blood–brain and blood–CSF barriers
well. In fact the intensive administration schedule required
for this drug to be effective is probably partly due to its
inability to rapidly cross the BBB. Eﬂornithine crosses the
blood–CNS interfaces by diffusion and eﬂornithine entry into
the CNS can be enhanced with suramin. This explains the
observed synergy of eﬂornithine-suramin combinations in
CNS efﬁcacy models and is the ﬁrst to demonstrate that
combination therapy can prove efﬁcacious due to enhanced
drug delivery to the CNS. Furthermore, this study also
illustrates that parasites reach the CNS early in the course of
infection, irreversible blood–brain and blood–CSF barrier
breakdown is unnecessary for parasites to reach the CNS,
parasites that cross the BBB in vivo remain viable, and
widespread BBB dysfunction occurs during the terminal
stage of the disease.
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